IU training prog. in molecular physiology and clinical mechanisms of lung disease

IU培训计划。

基本信息

项目摘要

DESCRIPTION (provided by applicant): This T-32 Training application is anchored within the Indiana University School of Medicine, the principal School of the Indiana University Purdue University at Indianapolis (lUPUI). The proposed training program in Lung Immunobiology is provided by a multidisciplinary, highly collaborative group of established investigators and highly qualified and dedicated mentors. We have included in the training program classical elements of basic and clinical-translational, research, adding on developing novel technologies. These research skills will enable our trainees to accelerate the advancements in lung research and close the gaps in knowledge that prevented for so many decades the development of phenotypic characterization, effective preventive intervention, and disease- modifying or even curative druts for most patients with lung disease. Being led by Program Director who is a renowned physician scientist and experienced mentor who himself is a minority, and having direct support from an experienced Minority Advisory Board, this application demonstrates our commitment to the development of a successful training program for under-represented and minority scientists. The Program Director will obtain continuous advise and feedback regarding the operation of the Training Grant from several internal and one external committee, composed of leaders in academic medicine If funded, this program will provide the only research training program of pulmonary physicians and scientists in the state of Indiana, which has one of the highest incidence of chronic lung diseases in the country.
描述(由申请人提供):此T-32培训申请锚定在印第安纳大学医学院,印第安纳大学普渡大学印第安纳波利斯分校(lUPUI)的校长学校。拟议的肺免疫生物学培训计划由一个多学科、高度协作的小组提供,该小组由成熟的研究人员和高素质、敬业的导师组成。我们在培训计划中纳入了基础研究和临床转化研究的经典要素,并增加了开发新技术的内容。这些研究技能将使我们的学员能够加速肺部研究的进展,并缩小几十年来阻碍大多数肺部疾病患者发展表型表征、有效预防干预、疾病修饰甚至治疗药物的知识差距。项目主管是一位著名的内科科学家,也是一位经验丰富的导师,他本人也是少数族裔,并得到了经验丰富的少数族裔顾问委员会的直接支持,这一申请表明了我们致力于为弱势群体和少数族裔科学家开发一个成功的培训项目。项目主任将从几个内部和一个外部委员会(由学术医学领导者组成)获得关于培训基金运作的持续建议和反馈。如果获得资助,该项目将提供印第安纳州唯一的肺病医生和科学家的研究培训项目,印第安纳州是美国慢性肺病发病率最高的州之一。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David S Wilkes其他文献

A 46-Year-Old Man With Excruciating Shoulder Pain
  • DOI:
    10.1378/chest.127.3.1039
  • 发表时间:
    2005-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Eric J Olafsson;Tallal Zeni;David S Wilkes
  • 通讯作者:
    David S Wilkes

David S Wilkes的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David S Wilkes', 18)}}的其他基金

TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    8713903
  • 财政年份:
    2010
  • 资助金额:
    $ 19.01万
  • 项目类别:
IL-17A and anti-col (V) humoral immunity in lung allograft rejection
IL-17A 和抗 col (V) 体液免疫在肺同种异体移植排斥反应中的作用
  • 批准号:
    7810371
  • 财政年份:
    2010
  • 资助金额:
    $ 19.01万
  • 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    8136215
  • 财政年份:
    2010
  • 资助金额:
    $ 19.01万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7810374
  • 财政年份:
    2010
  • 资助金额:
    $ 19.01万
  • 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    8317659
  • 财政年份:
    2010
  • 资助金额:
    $ 19.01万
  • 项目类别:
Renovation of the Wells Research Center for a Pediatric Phenotyping Core
威尔斯研究中心儿科表型分析核心的改造
  • 批准号:
    7935901
  • 财政年份:
    2010
  • 资助金额:
    $ 19.01万
  • 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    7765108
  • 财政年份:
    2010
  • 资助金额:
    $ 19.01万
  • 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
  • 批准号:
    8523761
  • 财政年份:
    2010
  • 资助金额:
    $ 19.01万
  • 项目类别:
IU training prog. in molecular physiology and clinical mechanisms of lung disease
IU培训计划。
  • 批准号:
    8065435
  • 财政年份:
    2009
  • 资助金额:
    $ 19.01万
  • 项目类别:
IU training prog. in molecular physiology and clinical mechanisms of lung disease
IU培训计划。
  • 批准号:
    8442828
  • 财政年份:
    2009
  • 资助金额:
    $ 19.01万
  • 项目类别:

相似海外基金

CMKLR1-Targeted Molecular Imaging of Inflammation as a Precision Medicine Tool in Acute Lung Injury and Fibrotic Lung Diseases
CMKLR1 靶向炎症分子成像作为急性肺损伤和纤维化肺疾病的精准医学工具
  • 批准号:
    10733483
  • 财政年份:
    2023
  • 资助金额:
    $ 19.01万
  • 项目类别:
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型分析研究中的 1/2 前瞻性治疗效果
  • 批准号:
    10385681
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型分析研究中的 1/2 前瞻性治疗效果
  • 批准号:
    10618152
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型分析研究中的 1/2 前瞻性治疗效果
  • 批准号:
    10026438
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
  • 批准号:
    10596595
  • 财政年份:
    2019
  • 资助金额:
    $ 19.01万
  • 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
  • 批准号:
    10385682
  • 财政年份:
    2019
  • 资助金额:
    $ 19.01万
  • 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
  • 批准号:
    10021690
  • 财政年份:
    2019
  • 资助金额:
    $ 19.01万
  • 项目类别:
RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung Diseases
RLDC:分子途径驱动的诊断
  • 批准号:
    8765116
  • 财政年份:
    2014
  • 资助金额:
    $ 19.01万
  • 项目类别:
RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung Diseases
RLDC:分子途径驱动的诊断
  • 批准号:
    9140225
  • 财政年份:
    2014
  • 资助金额:
    $ 19.01万
  • 项目类别:
RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung Diseases
RLDC:分子途径驱动的诊断
  • 批准号:
    9114659
  • 财政年份:
    2014
  • 资助金额:
    $ 19.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了